A memorandum to the President and Congress of the United States
This memorandum is to inform the United States President and Congress of a severe public safety hazard in the legislation governing medical device authorization by FDA.
This memorandum is to inform the United States President and Congress of a severe public safety hazard in the legislation governing medical device authorization by FDA.
The FDA, under the 1976 amendment to the Food, Drug and Cosmetics Act, is responsible for clearance of medical devices for marketing. The 1976 amendment included a premarket approval (PMA) process for safety testing of medical devices.
In 1976, many devices were already in the marketplace. Therefore, Congress included an alternative pathway to the PMA, known as 510(k). This provision aimed to provide a less burdensome route to facilitate access of newer versions of existing devices to the marketplace. Importantly, the 510(k) pathway did not require any clinical trials or manufacturing inspections to demonstrate device safety.
With the advent of the Medical Device User Fee and Modernization Act in 2002, the FDA was guided to shift its regulatory standard to "the least burdensome approach in all areas of medical device regulation." As a result, FDA currently authorizes the marketing of the majority of medical devices via the 510(k) pathway. Functionally, this shift guaranteed that the vast majority of newly FDA authorized medical devices in the United States are not safety tested. More Importantly, the 510(k) pathway fails to provide FDA with an adequate post-market surveillance or reporting mandate. Therefore, severe adverse outcomes can go entirely undetected by federal regulators.
In 2011, as a result of several emerging safety concerns, the Institute of Medicine analyzed the 510(k) provision and concluded in formal testimony to the United States Senate's HELP committee that it "does not and can not ensure patient safety". At that time, congress elected to maintain the 510(k) provision and did not revise it.
In December 2013, the Wall Street Journal recognized and reported that an FDA authorized medical device known as a "power morcellator", and widely used by gynecological surgeons in the US and abroad, was responsible for spreading and upstaging aggressive cancers in one in 350 American women undergoing hysterectomy. Many American families, for over 2 decades, have been irreversibly harmed as a result. The FDA has confirmed that this deadly hazard was masked from agency regulators until December 2013. Investigative reporting by the WSJ subsequently demonstrated that the "morcellator disaster" was, in great part, caused by the safety failure in FDA's 510(k) provision.
The power morcellator case is a bellwether case for medical device safety in the United States. It demonstrates the need for immediate reform of the 510(k) provision to ensure the safety of American patients.
The danger posed to public health by the 510(k) amendment is clear and present. It is, therefore, recommended that the president immediately call for a revision to 510(k) that would: 1) more stringently define medical devises eligible for authorization via the 510(k) pathway and 2) include an effective and enforceable post-market surveillance and reporting mechanism for detection of adverse outcomes associated with the use of medical devices in the United States.
Hooman Noorchashm and Amy Reed, husband-and-wife physicians, have campaigned to ban electric morcellators since December 2013, soon after Reed's unsuspected uterine cancer was spread by the device during a routine hysterectomy.
Read more from the Check Up blog »























